Ovarian cancer often presents at an advanced stage with frequent relapse despite optimal treatment, thus, accurate restaging is required for improving treatment outcomes and prognosis. Conventionally, detection of recurrent lesions is performed by using gynecologic examination, serum CA125(cancer antigen-125), computed tomography(CT) and magnetic resonance imaging(MRI). Recently, positron emission tomography(PET) or PET/CT, in addition to metabolic biomarkers, are found to be associated with improvement of optimal secondary surgery and progression-free survival in patients with recurrent ovarian cancer.